NEOS Investment Management LLC Has $846,000 Stock Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

NEOS Investment Management LLC lifted its position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 10.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 25,735 shares of the biopharmaceutical company’s stock after buying an additional 2,527 shares during the quarter. NEOS Investment Management LLC’s holdings in Agios Pharmaceuticals were worth $846,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. Venturi Wealth Management LLC bought a new stake in Agios Pharmaceuticals during the 4th quarter valued at approximately $33,000. Wingate Wealth Advisors Inc. acquired a new position in shares of Agios Pharmaceuticals during the fourth quarter worth approximately $53,000. KBC Group NV boosted its position in shares of Agios Pharmaceuticals by 30.5% in the fourth quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company’s stock valued at $86,000 after acquiring an additional 611 shares during the period. Quantbot Technologies LP bought a new position in Agios Pharmaceuticals during the third quarter worth $146,000. Finally, AlphaQuest LLC raised its stake in Agios Pharmaceuticals by 106.2% during the 4th quarter. AlphaQuest LLC now owns 4,540 shares of the biopharmaceutical company’s stock valued at $149,000 after purchasing an additional 2,338 shares during the last quarter.

Analyst Ratings Changes

A number of brokerages have weighed in on AGIO. HC Wainwright initiated coverage on shares of Agios Pharmaceuticals in a report on Monday, February 24th. They issued a “buy” rating and a $58.00 price target for the company. StockNews.com cut shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, February 14th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Agios Pharmaceuticals in a report on Wednesday, December 18th. Scotiabank raised their price objective on Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a research report on Monday, December 9th. Finally, Royal Bank of Canada boosted their price objective on Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a research report on Tuesday, December 10th. One analyst has rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $56.57.

Insider Activity

In other news, insider Tsveta Milanova sold 2,804 shares of the firm’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $32.18, for a total transaction of $90,232.72. Following the completion of the sale, the insider now owns 18,906 shares of the company’s stock, valued at approximately $608,395.08. This trade represents a 12.92 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 4.93% of the stock is owned by corporate insiders.

Agios Pharmaceuticals Trading Down 1.8 %

AGIO stock opened at $30.28 on Monday. Agios Pharmaceuticals, Inc. has a 1-year low of $27.14 and a 1-year high of $62.58. The business’s 50 day moving average is $33.17 and its 200-day moving average is $40.82. The firm has a market cap of $1.73 billion, a P/E ratio of 2.67 and a beta of 0.90.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) EPS for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. Sell-side analysts forecast that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current year.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.